# High-Risk Skin Cancers With Atezolizumab Plus NT-I7

> **NCT03901573** · PHASE1,PHASE2 · TERMINATED · sponsor: **NeoImmuneTech** · enrollment: 31 (actual)

## Conditions studied

- Melanoma
- Merkel Cell Carcinoma
- Cutaneous Squamous Cell Carcinoma

## Interventions

- **DRUG:** NT-I7
- **DRUG:** atezolizumab

## Key facts

- **NCT ID:** NCT03901573
- **Lead sponsor:** NeoImmuneTech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-12-26
- **Primary completion:** 2023-08-15
- **Final completion:** 2023-08-15
- **Target enrollment:** 31 (ACTUAL)
- **Why stopped:** Strategic decision by sponsor
- **Last updated:** 2025-10-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03901573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03901573, "High-Risk Skin Cancers With Atezolizumab Plus NT-I7". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03901573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*